Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q4 FY20 results · Jan–Mar 2020
Panacea Biotec reported revenue from operations of ₹125.36 crore and net loss of ₹69.70 crore for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 125.36 | — | — | 167.74 | −25.3% |
| Other income | 17.98 | — | — | 3.23 | +456.7% |
| Total income | 143.34 | — | — | 170.97 | −16.2% |
| Profit before share of associates & JVs and tax | (59.40) | — | — | (17.90) | Loss widened |
| Share of profit/(loss) of associates & JVs | 0.16 | — | 0.07 | ||
| Net profit for the period | (69.70) | — | — | (21.32) | Loss widened |
| EPS, basic (₹) | (11.38) | — | — | (3.48) | Loss widened |
| Net margin (%) | -55.6 | — | -12.7 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 56.77 | 29.26 | +94.0% | 55.52 | +2.3% |
| Other income | 27.80 | 1.13 | 25x | 1.16 | 24x |
| Total income | 84.57 | 30.39 | +178.3% | 56.68 | +49.2% |
| Profit before tax | (6.62) | 218.69 | Turned loss | 1.05 | Turned loss |
| Net profit for the period | (32.48) | 183.90 | Turned loss | (19.74) | Loss widened |
| EPS, basic (₹) | (5.31) | 30.02 | Turned loss | (3.23) | Loss widened |
| Net margin (%) | -57.2 | 628.5 | -35.6 |
Consolidated
- Filed with BSE
- 03 Jul 2020, 16:23 IST
- Board meeting
- 29 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 03 Jul 2020, 16:23 IST
- Board meeting
- 29 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE